clocortolone (cloderm) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Clocortolone (used in form of pivalate prodrug) is a topical glucocorticoid that was approved by FDA for the treatment of corticosteroid-responsive skin disorders. The drug exerts its anti-inflammatory action by binding to glucocorticoid receptor which results in regulation of the expression of proinflammatory cytokines and further antiproliferative, immunosuppressive, and initial vasoconstrictive effects.   NCATS

Chemistry

  • SMILES: C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
  • InChIKey: YMTMADLUXIRMGX-RFPWEZLHSA-N
  • Mol. Mass: 410.907
  • ALogP: 4.6
  • ChEMBL Molecule:
    clocortolone pivalate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: No

Drug Pricing (per unit)

United States

$3.0257 - $511.2800
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

9 alpha-chloro-6 alpha-fluoro-11 beta,21- dihydroxy-16 alpha-methylpregna-1,4-diene-3,20- dione 21-pivalate | 9-chloro-6alpha-fluoro-11beta,21-dihydroxy-16alpha-methyl-1,4-pregnadien-3,20-dione | 9-chloro-6 alpha-fluoro-11 beta,21-dihydroxy- 16 alpha-methylpregnadiene-3,20-dione 21-acetate | 9-chloro-6alpha-fluoro-16alpha-methyl-1,4-pregnadiene-11beta,21-diol-3,20-dione | cl 68 | clocortolon | clocortolona | clocortolone | clocortolone acetate | clocortolone pivalate | clocortolone trimethylacetate | clocortolonum | cloderm | purantix | sh-863

Organizations (5)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (1)


 

Skin Diseases (approved 1977)

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Drugs, Generic (Phase 1)

Psoriasis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue